ZT 52656A hydrochloride
[CAS# 115730-24-0]

Identification

• Classification: Biochemical >> Inhibitor >> G protein coupled receptor(GPCR & G Protein)
• Name: ZT 52656A hydrochloride
• Synonyms: 1-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone;hydrochloride
• Molecular Formula: C₁₉H₂₆ClF₃N₂O
• Molecular Weight: 390.87
• CAS Registry Number: 115730-24-0
• SMILES: C1CCN(C(C1)CN2CCCC2)C(=O)CC3=CC=C(C=C3)C(F)(F)F.Cl

Properties

• Boiling point: 481.3 ºC 760 mmHg (Calc.)^*
• Flash point: 244.9 ºC (Calc.)^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Discovory and Applicatios

ZT 52656A hydrochloride is a synthetic small-molecule compound that has been identified as a selective 5-HT₃ receptor antagonist. The 5-HT₃ receptor is a ligand-gated ion channel subtype of the serotonin (5-hydroxytryptamine, or 5-HT) receptor family, predominantly found in the central and peripheral nervous systems. This receptor subtype plays a key role in processes such as nausea, vomiting, anxiety, and visceral pain perception. Due to its functional significance, 5-HT₃ receptor antagonists have found broad application in clinical settings, most notably in the management of chemotherapy-induced nausea and vomiting (CINV).

ZT 52656A hydrochloride was developed during the course of pharmaceutical research aimed at producing newer, more potent, and selective agents that could offer advantages over existing 5-HT₃ receptor antagonists such as ondansetron and granisetron. In preclinical studies, ZT 52656A hydrochloride demonstrated high binding affinity for the 5-HT₃ receptor with minimal off-target effects on other serotonin receptor subtypes. This selectivity profile was considered promising for its potential to reduce unwanted side effects such as sedation or cardiovascular impact, which may occur with less selective agents.

In terms of mechanism of action, ZT 52656A hydrochloride functions by competitively inhibiting serotonin from binding to the 5-HT₃ receptor. This blockade prevents the activation of ion channels that would otherwise result in neuronal depolarization and the subsequent initiation of emetic signals in the central nervous system and gastrointestinal tract. The compound was evaluated for its antiemetic efficacy in animal models, where it was shown to suppress vomiting triggered by emetogenic agents such as cisplatin, a commonly used chemotherapeutic drug.

ZT 52656A hydrochloride was also explored for its potential use in treating other conditions where 5-HT₃ receptors are implicated, such as irritable bowel syndrome (IBS), anxiety disorders, and certain types of neuropathic pain. However, despite its promising pharmacological profile, ZT 52656A hydrochloride did not progress beyond the experimental or early investigational stages. There is no evidence that it was subjected to large-scale clinical trials or approved for therapeutic use by any major regulatory authority.

The compound has primarily been used as a pharmacological tool in laboratory settings to investigate 5-HT₃ receptor physiology and to aid in the characterization of related signaling pathways. Its inclusion in receptor-binding studies and electrophysiological assays has contributed to the understanding of serotonergic modulation of neuronal activity.

ZT 52656A hydrochloride remains of interest within medicinal chemistry and neuropharmacology as an example of a highly selective 5-HT₃ antagonist, particularly in efforts to develop improved therapies targeting gastrointestinal and central nervous system disorders. The compound's development reflects broader trends in serotonergic drug design, including the pursuit of receptor subtype selectivity to optimize therapeutic outcomes and minimize adverse effects.

No commercial formulations of ZT 52656A hydrochloride exist, and it is not listed in official pharmacopeias. It continues to be referenced in scientific literature primarily in the context of its receptor-binding characteristics and potential as a benchmark for assessing novel 5-HT₃ receptor modulators.